New drug combo aims to fight tough stomach cancers

NCT ID NCT05332002

Recruiting now Disease control Sponsor: Rutgers, The State University of New Jersey Source: ClinicalTrials.gov ↗

Summary

This study is testing a combination of chemotherapy drugs (called sFOLFOXIRI) for people with advanced stomach or esophageal cancer that has spread and cannot be removed by surgery. The main goal is to see how well this treatment shrinks tumors and controls the cancer's growth. Researchers will also track how long patients live and monitor side effects to see if the treatment is safe and tolerable.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

RWJBarnabas Health - Monmouth Medical Center
RECRUITING

Long Branch, New Jersey, 07740, United States

Contact
RWJBarnabas Health - Monmouth Medical Center Southern Campus
RECRUITING

Lakewood, New Jersey, 08701, United States

Contact
RWJBarnabas Health - Newark Beth Israel Medical Center
RECRUITING

Newark, New Jersey, 07112, United States

Contact
RWJBarnabas Health - Robert Wood Johnson University Hospital
RECRUITING

Hamilton, New Jersey, 08690, United States

Contact
RWJBarnabas Health - Robert Wood Johnson University Hospital, Somerset
RECRUITING

New Brunswick, New Jersey, 08903, United States

Contact
Rutgers Cancer Institute of New Jersey
RECRUITING

New Brunswick, New Jersey, 08903, United States

Contact

Conditions

Explore the condition pages connected to this study.

GASTRO-INTESTINAL CANCER